Trials / Recruiting
RecruitingNCT07268040
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-7787 Injection | SHR-7787 Injection. |
| DRUG | SHR-1316 Injection | SHR-1316 Injection. |
| DRUG | SHR-4849 Injection | SHR-4849 Injection. |
| DRUG | Etoposide injection | Etoposide Injection. |
| DRUG | Carboplatin injection | Carboplatin Injection. |
| DRUG | Cisplatin injection | Cisplatin Injection. |
| DRUG | BP102 Injection | BP102 Injection. |
Timeline
- Start date
- 2025-12-23
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-12-05
- Last updated
- 2026-01-12
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07268040. Inclusion in this directory is not an endorsement.